Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 2, Février 2013
Page(s) 189 - 193
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2013292017
Publié en ligne 28 février 2013
  1. Loriot MA, Beaune P. La pharmacogénétique : le lien entre gènes et réponse aux médicaments. Med Sci (Paris) 2004 ; 20 : 634–636. [CrossRef] [EDP Sciences] [PubMed]
  2. Vogel F. Moderne Probleme der Humangenetik. Ergebn Inn Med Kinderheilkd 1959 ; 12 : 52–125. [CrossRef]
  3. Woelderink A, Ibarreta D, Hopkins MM, Rodriguez-Cerezo E. The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J 2006 ; 6 : 3–7. [CrossRef] [PubMed]
  4. Begley CE, Baker GA, Beghi E, et al. Cross-country measures for monitoring epilepsy care. Epilepsia 2007 ; 48 : 990–1001. [CrossRef] [PubMed]
  5. Reutens DC, Howell RA, Gebert KE, Berkovic SF. Validation of a questionnaire for clinical seizure diagnosis. Epilepsia 1992 ; 33 : 1065–1071. [CrossRef] [PubMed]
  6. Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology 2009 ; 72 : 1223–1229. [CrossRef] [PubMed]
  7. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011 ; 364 : 1126–1133. [CrossRef] [PubMed]
  8. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004 ; 428 : 86. [CrossRef]
  9. Devinsky O. Patients with refractory seizures. N Engl J Med 1999 ; 340 : 1565–1570. [CrossRef] [PubMed]
  10. Tan NC, Berkovic SF. The Epilepsy Genetic Association Database (epiGAD): analysis of 165 genetic association studies, 1996–2008. Epilepsia 2010 ; 51 : 686–689. [CrossRef] [PubMed]
  11. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. Am J Hum Genet 2000 ; 67 : 170–181. [CrossRef] [PubMed]
  12. Loscher W, Sills G J. Drug resistance in epilepsy: why is a simple explanation not enough? Epilepsia 2007 ; 48 : 2370–2372. [CrossRef] [PubMed]
  13. Sisodiya SM, Lin WR, Harding BN, et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002 ; 125 : 22–31. [CrossRef] [PubMed]
  14. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002 ; 301 : 7–14. [CrossRef] [PubMed]
  15. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003 ; 348 : 1442–1448. [CrossRef] [PubMed]
  16. Bournissen FG, Moretti ME, Juurlink DN, et al. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 2009 ; 50 : 898–903. [CrossRef] [PubMed]
  17. Haerian BS, Roslan H, Raymond AA, et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. Seizure 2010 ; 19 : 339–346. [CrossRef] [PubMed]
  18. Nurmohamed L, Garcia-Bournissen F, Buono RJ, et al. Predisposition to epilepsy–does the ABCB1 gene play a role?. Epilepsia 2010 ; 51 : 1882–1885. [CrossRef] [PubMed]
  19. Baltes S, Fedrowitz M, Tortos CL, et al. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007 ; 320 : 331–343. [CrossRef] [PubMed]
  20. Aynacioglu AS, Brockmoller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999 ; 48 : 409–415. [CrossRef] [PubMed]
  21. Depondt C, Godard P, Sens Espel R, et al. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol 2011 ; 18 : 1153–1164. [CrossRef]
  22. Tate S K, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005 ; 102 : 5507–5512. [CrossRef]
  23. Gambardella A, Marini C. Clinical spectrum of SCN1A mutations. Epilepsia 2009 ; 50 : 20–23. [CrossRef] [PubMed]
  24. Abe T, Seo T, Ishitsu T, et al. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol 2008 ; 66 : 304–307. [CrossRef] [PubMed]
  25. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006 ; 16 : 297–306. [CrossRef] [PubMed]
  26. Alfirevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006 ; 7 : 813–818. [CrossRef] [PubMed]
  27. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006 ; 6 : 265–268. [PubMed]
  28. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011 ; 364 : 1134–1143. [CrossRef] [PubMed]
  29. Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011 ; 20 : 1034–1041. [CrossRef] [PubMed]
  30. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 2010 ; 11 : 415–425. [CrossRef] [PubMed]
  31. Roujeau JC, Gélard K, Bensussan A. Nécrolyse épidermique : Mécanisme de l’apoptose des kératinocytes. Med Sci (Paris) 2006 ; 22 : 188–191. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.